HK Stock Price Fluctuated | The concept of innovative drugs continues to rise as KINTOR PHARMA-B (09939) surges over 15%. Institutions claim that the situation of medical insurance negotiations is turning optimistic.

The concept of innovative drugs continued to rise in the morning session. As of the time of writing, KINTOR PHARMA-B (09939) rose 15.25% to HKD 3.4; HUA MEDICINE-B (02552) rose 9.04% to HKD 2.05; KEYMED BIO-B (02162) rose 5.25% to HKD 56.1; and BRII-B (02137) rose 3.77% to HKD 2.75. In terms of news, the medical insurance negotiation officially began last Friday and lasted for 4 days in Beijing. A total of 168 drugs entered the negotiation bidding phase, involving rare disease drugs, anti-tumor drugs, antiviral drugs, and domestically innovative drugs. The adjusted catalog results are expected to be announced in early December this year, and the new version of medical insurance catalog will be officially implemented from January 1st next year. Huaan pointed out that the overall negotiation feedback is better. Combined with the policy adjustments made this year, the evaluation methods and specific rules have been further optimized and improved, fully reflecting the value-based purchasing of medical insurance and support for medical innovation, providing positive returns to innovative drugs. Tianfeng also stated that it is expected that under the new renewal rules, the extent of price reduction by each company will be smaller than expected, which will subsequently promote higher sales growth and peak sales for drugs.